Boston Scientific (BSX) Reports 22.4% Net Sales Growth in Q4 2024

By Bobby Samwell • Wednesday, February 05 10:25 • Permanent Link

Boston Scientific Corporation (NYSE: BSX) has reported its financial results for the fourth quarter and full year of 2024. The company's net sales during the fourth quarter of 2024 were $4.561 billion, marking an impressive 22.4% increase compared to the prior year period. On a reported basis, the company's net sales grew by 22.4%, while the operational and organic basis saw growth of 23.1% and 19.5% respectively.

In terms of GAAP net income attributable to Boston Scientific common stockholders, the company reported $566 million or $0.38 per share, compared to $504 million or $0.34 per share a year ago. The adjusted EPS for the period was $0.70, a significant increase from $0.55 a year ago.

For the full year 2024, Boston Scientific generated net sales of $16.747 billion, reflecting a substantial 17.6% growth on a reported basis, 18.5% on an operational basis, and 16.4% on an organic basis, all compared to the prior year period. The company also reported GAAP net income attributable to Boston Scientific common stockholders of $1.853 billion or $1.25 per share, compared to $1.570 billion or $1.07 per share a year ago. The full year adjusted EPS was $2.51, compared to $2.05 a year ago.

In the fourth quarter, Boston Scientific's MedSurg segment reported net sales growth of 12.4% reported, 13.0% operational, and 7.0% organic. The Cardiovascular segment saw even more impressive growth, with net sales increasing by 28.8% reported, 29.5% operational, and 27.4% organic. Geographically, the United States demonstrated robust performance with 30.7% reported and operational net sales growth.

Looking ahead, Boston Scientific estimates net sales growth for the full year 2025 to be in a range of approximately 12.5 to 14.5% on a reported basis and approximately 10 to 12% on an organic basis. The company also provided EPS guidance, estimating a range of $1.86 to $1.93 on a GAAP basis and adjusted EPS of $2.80 to $2.87.

Today the company's shares have moved 2.4% to a price of $106.0. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.